Literature DB >> 15802273

Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.

Terence M Williams1, Ghada S Hassan, Jiangwei Li, Alex W Cohen, Freddy Medina, Philippe G Frank, Richard G Pestell, Dolores Di Vizio, Massimo Loda, Michael P Lisanti.   

Abstract

Caveolin-1 (Cav-1) is the primary structural component of caveolae and is implicated in the processes of vesicular transport, cholesterol balance, transformation, and tumorigenesis. Despite an abundance of data suggesting that Cav-1 has transformation suppressor properties both in vitro and in vivo, Cav-1 is expressed at increased levels in human prostate cancer. To investigate the role of Cav-1 in prostate cancer onset and progression, we interbred Cav-1(-/-) null mice with a TRAMP (transgenic adenocarcinoma of mouse prostate) model that spontaneously develops advanced prostate cancer and metastatic disease. We found that, although the loss of Cav-1 did not affect the appearance of minimally invasive prostate cancer, its absence significantly impeded progression to highly invasive and metastatic disease. Inactivation of one (+/-) or both (-/-) alleles of Cav-1 resulted in significant reductions in prostate tumor burden, as well as decreases in regional lymph node metastases. Moreover, further examination revealed decreased metastasis to distant organs, such as the lungs, in TRAMP/Cav-1(-/-) mice. Utilizing prostate carcinoma cell lines (C1, C2, and C3) derived from TRAMP tumors, we also showed a positive correlation between Cav-1 expression and the ability of these cells to form tumors in vivo. Furthermore, down-regulation of Cav-1 expression in these cells, using a small interfering RNA approach, significantly reduced their tumorigenic and metastatic potential. Mechanistically, we showed that loss or down-regulation of Cav-1 expression results in increased apoptosis, with increased prostate apoptosis response factor-4 and PTEN levels in Cav-1(-/-) null prostate tumors. Our current findings provide the first in vivo molecular genetic evidence that Cav-1 does indeed function as a tumor promoter during prostate carcinogenesis, rather than as a tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15802273     DOI: 10.1074/jbc.M501186200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1.

Authors:  Sudjit Luanpitpong; Siera Jo Talbott; Yon Rojanasakul; Ubonthip Nimmannit; Varisa Pongrakhananon; Liying Wang; Pithi Chanvorachote
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Authors:  Guang Yang; Alexei A Goltsov; Chengzhen Ren; Shinji Kurosaka; Kohei Edamura; Richard Logothetis; Francesco J DeMayo; Patricia Troncoso; Jorge Blando; John DiGiovanni; Timothy C Thompson
Journal:  Mol Cancer Res       Date:  2011-12-05       Impact factor: 5.852

3.  MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction.

Authors:  Ulf Andersson Ørom; Meng K Lim; Jason E Savage; Lianjin Jin; Anthony D Saleh; Michael P Lisanti; Nicole L Simone
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

4.  Effect of Dachengqi decoction on NF-kappaB p65 expression in lung of rats with partial intestinal obstruction and the underlying mechanism.

Authors:  Shenglan Yang; Lin Shen; Yang Jin; Jianguo Liu; Jiechang Gao; Daoben Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

5.  Proteome-wide dysregulation by PRA1 depletion delineates a role of PRA1 in lipid transport and cell migration.

Authors:  Hao-Ping Liu; Chih-Ching Wu; Hung-Yi Kao; Yi-Chuan Huang; Ying Liang; Chia-Chun Chen; Jau-Song Yu; Yu-Sun Chang
Journal:  Mol Cell Proteomics       Date:  2010-06-30       Impact factor: 5.911

6.  Statins and prostate cancer diagnosis and grade in a veterans population.

Authors:  Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano
Journal:  J Natl Cancer Inst       Date:  2011-04-15       Impact factor: 13.506

Review 7.  Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes.

Authors:  Michael R Freeman; Bekir Cinar; Jayoung Kim; Nishit K Mukhopadhyay; Dolores Di Vizio; Rosalyn M Adam; Keith R Solomon
Journal:  Steroids       Date:  2006-12-14       Impact factor: 2.668

8.  Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth.

Authors:  Huajun Zhao; Yuan-Hung Lo; Li Ma; Susan E Waltz; Jerilyn K Gray; Mien-Chie Hung; Shao-Chun Wang
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

9.  Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.

Authors:  Arthur C-K Chung; Suoling Zhou; Lan Liao; Jean Ching-Yi Tien; Norman M Greenberg; Jianming Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

10.  Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.

Authors:  Likun Li; Chengzhen Ren; Guang Yang; Alexei A Goltsov; Ken-ichi Tabata; Timothy C Thompson
Journal:  Mol Cancer Res       Date:  2009-11-10       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.